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Abstract
Background Autosomal recessive polycystic kidney disease (ARPKD) is genetically one of the least heterogeneous ciliopathies,
resulting primarily from mutations of PKHD1. Nevertheless, 13–20% of patients diagnosed with ARPKD are found not to carry
PKHD1 mutations by sequencing. Here, we assess whether PKHD1 copy number variations or second locus mutations explain
these cases.
Methods Thirty-six unrelated patients with the clinical diagnosis of ARPKD were screened for PKHD1 point mutations and
copy number variations. Patients without biallelic mutations were re-evaluated and screened for second locus mutations targeted
by the phenotype, followed, if negative, by clinical exome sequencing.
Results Twenty-eight patients (78%) carried PKHD1 point mutations, three of whom on only one allele. Two of the three patients
harbored in trans either a duplication of exons 33–35 or a large deletion involving exons 1–55. All eight patients without PKHD1
mutations (22%) harbored mutations in other genes (PKD1 (n = 2), HNF1B (n = 3), NPHP1, TMEM67, PKD1/TSC2). Perinatal
respiratory failure, a kidney length > +4SD and early-onset hypertension increase the likelihood of PKHD1-associated ARPKD.
A patient compound heterozygous for a second and a last exon truncating PKHD1mutation (p.Gly4013Alafs*25) presented with
a moderate phenotype, indicating that fibrocystin is partially functional in the absence of its C-terminal 62 amino acids.
Conclusions We found all ARPKD cases without PKHD1 point mutations to be phenocopies, and none to be explained by
biallelic PKHD1 copy number variations. Screening for copy number variations is recommended in patients with a heterozygous
point mutation.
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Introduction
Autosomal recessive polycystic kidney disease (ARPKD) be-
longs to the family of primary cilia-related diseases. Though
more than 70 genes have been identified in ciliopathies [1], the
genetic homogeneity of ARPKD makes it unique: it is princi-
pally caused by mutations of PKHD1 [2]. Recently, mutations
of a second gene, DZIP1L, have been identified [3] and pro-
moter mutation of PMM2was recently described in polycystic
kidney disease and hyperinsulinemic hypoglycemia [4].
PKHD1 is expressed in the renal collecting ducts and in the
hepatic bile ducts. The encoded protein, fibrocystin, has a
receptor-like structure, and plays a role in maintaining calcium
homeostasis [5]. Fibrocystin interacts with polycystin-2, a cal-
cium channel, and is also regulated by polycystin-1 [6–9].
Their role in a common pathway seems to explain the similar
renal manifestations of patients with biallelic PKD1 or PKD2
mutations [10, 11]. The expression of fibrocystin—besides
other ciliary proteins—is regulated by HNF1B. Its haploinsuf-
ficiency is a common cause of cystic kidney dysplasia, diag-
nosed often as a hyperechogenic kidney in utero, which can
also mimic perinatally a mild form of ARPKD [12–14]. The
clinical presentation of severe ARPKD is highly specific: it is
typically diagnosed in utero, with oligohydramnios and ex-
tremely enlarged, hyperechogenic kidneys. Thirty percent of
the affected children die perinatally because of secondary pul-
monary hypoplasia [15]. The diagnosis of mild cases can
however be challenging [15]. In these cases, kidneys can be
even normal sized, though not smaller than the height-
matched median [16]. Hepatic fibrosis (HF) is an obligate
feature in ARPKD, secondary to defective remodeling of the
ductal plate and hyperplastic biliary ducts [17–19].
Nevertheless, its severity is highly variable, and in most cases,
it is difficult to detect by ultrasound scan [18–20]. The asso-
ciation of hepatic fibrosis to cystic kidneys is common in
ciliopathies, most typically in NPHP3- and TMEM67-associ-
ated nephronophthisis [21, 22]. Since these can also result in
above-average sized hyperechogenic kidneys, their clinical
differential diagnosis can also be challenging. Overlapping
phenotypes secondary to the influence of second loci or epi-
genetic factors can further complicate the genetic diagnosis
[16, 23, 24].
Genetic confirmation of the diagnosis is demanding for
several reasons: PKHD1 is one of the largest genes consisting
of 67 exons in its largest transcript, with more than 700 known
mutations (URL: http://www.humgen.rwth-aachen.de) [25].
Furthermore, PKHD1 copy number variations (CNVs),
which are difficult to detect by sequencing, have been
described in some cases [15, 25–27]. Finally, the cumulative
allele frequency of its mutations is the highest among all
ciliopathy genes, resulting in a carrier frequency of 1.5% in
the Caucasian population [28]. Therefore, a heterozygous
PKHD1 mutation is a relatively common incidental finding,
and does not necessarily mean the trans-association of an un-
detected mutation in an affected patient.
Despite the principal role of PKHD1 in ARPKD, no
PKHD1 mutations are identified in 13–20% of the cases by
sequencing [15, 16, 27, 29–33]. Here we wanted to find the
reason for these cases: whether they result from undetected
PKHD1mutations or from second locus mutations. We there-
fore aimed to identify the causal mutations in all cases within a
cohort of 36 patients diagnosed with ARPKD by sequencing
and multiplex ligation-dependent probe amplification
(MLPA) analysis of PKHD1, followed, if negative, by muta-
tional screening of second locus mutations and by clinical
exome sequencing. We show that the cases negative for
PKHD1 point mutations are phenocopies.
Materials and methods
Patients
Thirty-six unrelated patients from four Hungarian pediatric
nephrology centers were included, based on the following
criteria: (1) hyperreflective kidneys with microcysts (< 2 cm
in diameter) on ultrasound, (2) a kidney length above the 50th
percentile (http://radiology-universe.org/calculator/pediatric-
kidney-sizes/calculator.php) on at least one side, (3) a trans-
mission compatible with autosomal recessive inheritance, (4)
no urinary tract malformation and (5) no extra-renal and -
hepatic involvement suggestive of other ciliopathies. None
of the families was known to be consanguineous. Parents
and patients gave informed written consent.
Screening for PKHD1 mutations
Genomic DNAwas isolated from peripheral blood by stan-
dard methods. The exons and intronic junctions were am-
plified using the primers described by Losekoot et al. [34]
and Sanger sequenced on an ABI Prism 310 Genetic
Analyzer (Thermo Fischer Scientific, Waltham, MA,
USA). Patients without biallelic point mutations were sub-
sequently screened for CNVs by MLPA, performed accord-
ing to the manufacturer’s instructions (MRC-Holland,
Amsterdam, the Netherlands). Briefly, DNAwas denatured
and hybridized overnight with the probe mixes P341 and
P342. Hybridized probes were ligated, and amplified with
5′-labeled fluorescent primers. Following separation on an
ABI Prism 310 Genetic Analyzer, copy numbers were cal-
culated based on the normalized peak heights following
intra- and intersample normalization. Parental samples were
screened for the identified mutations to confirm segregation
and trans-heterozygosity.
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Table 1 Clinical characteristics of patients with PKHD1 mutations. aBefore end-stage renal disease; bBorn on 29. gw, cborn on 31. gw; AS: abnormal
structure, CHS: cholestasis, CRF: chronic renal failure, d(s): day(s), dg: diagnosis, Diam.: diameter, ELE: elevated liver enzymes, ESRD: end-stage renal
disease, F: fibrosis, Fam: family, gw: gestational week, het: heterozygous, HM: hepatomegaly, hom: homozygous, HSM: hepatosplenomegaly, HT:
hypertension; inv.: involvement, IU: intrauterine; KTx: kidney transplant, LC: liver cysts, LTx: liver transplant m:maternal, mth(s): month(s), N: normal,
NA: not applicable, ND: no data, p: paternal, P/Pt: patient, Resp: respiratory, RF: renal failure, SDS: standard deviation score, w(s): week(s), yr(s):
year(s)
Fam. Pt PKHD1 mutation Exon Amino acid change Last follow-up/death
(age)
Resp. failure Age at dg of
kidney inv.
F1 P1 c.107C > T hom (m,p) 3 p.Thr36Met KTx:4 yrs – neonate
F2 P2 c.6992 T >A het (p) 43 p.Ile2331Lys 8 yrs + neonate
c.7916C >A het (m) 51 p.Ser2639*
F3 P3 c.8935C > T het (m) 58 p.Arg2979* † 6 ds + IU
c.7916C >A het (p) 51 p.Ser2639*
F4 P4 c.107C > T het(p) 3 p.Thr36Met 8 yrs + 1 mth
c.6992 T >A het (m) 43 p.Ile2331Lys
F5 P5 c.10658 T > C het (p) 65 p.Ile3553Thr 11 yrs – 4 yrs
c.7122delT het (m) 46 p.Phe2374Leufs*41
F6 P6 c.107C > T het (p) 3 p.Thr36Met † 3 mths + neonate
c.474G>A het (m) 7 p.Trp158*
F7 P7 c.7916C >A hom (m,p) 51 p.Ser2639* † 7 wsb + IU
F8 P8 c.107C > T hom (m,p) 3 p.Thr36Met † 6 ws + neonate
F9 P9 c.107C > T het 3 p.Thr36Met † 3 ds + neonate
c.7916C >A het 51 p.Ser2639*
F10 P10 c.5513A >G het (p) 34 p.Tyr1838Cys KTx:4 yrs + neonate
c.3463C > T het (m) 30 p.Gln1155*
F11 P11 c.3747 T >G het (p) 32 p.Cys1249Trp 12 yrs + IU (32.gw)
c.5513A >G het (m) 34 p.Tyr1838Cys
F12 P12 c.7916C >A het (m) 51 p.Ser2639* KTx:25 yrs – 7 yrs
c.10658 T > C het (p) 65 p.Ile3553Thr
F13 P13 c.547C > T het (p) 8 p.Gln183* 14 yrs – IU (30.gw)
c.4870C > T het (m) 32 p.Arg1624Trp
F14 P14 c.5_8delCTGC het (p) 2 p.Ala3Glyfs*2 15 yrs – 5 mths
c.12036delA het (m) 71 p.Gly4013Alafs*25
F15 P15 c.107C > T het (p) 3 p.Thr36Met 6 yrs + neonate
c.8552 T > C het (m) 55 p.Ile2851Thr
F16 P16 c.664A>G het (m) 9 p.Ile222Val 8 yrs – infancy
c.5513A >G het (p) 34 p.Tyr1838Cys
F17 P17 c.107C > T het (p) 3 p.Thr36Met 5 yrs – 3 mths
c.664A>G het (m) 9 p.Ile222Val
F18 P18 c.2341C > T het (p) 23 p.Arg781* 17 yrs – 16 yrs
c.10621A > T het (m) 65 p.Asn3541Tyr
F19 P19 c.7916C >A hom (m,p) 51 p.Ser2639* † 3 ws + IU
F20 P20 c.4328G >A het (m) 32 p.Cys1443Tyr 4,5 yrs + neonate
c.8870 T > C het (p) 58 p.Ile2957Thr
F21 P21 c.107C > T het 3 p.Thr36Met † 1 d + IU (32.gw)
c.5088delTG het 32 p.Gly1696fs*1
F22 P22 c.107C > T hom (m,p) 3 p.Thr36Met KTx:1.8 yrs + IU (33.gw)
F23 P23 c.107C > T hom (m,p) 3 p.Thr36Met † 6 ws + neonate
F24 P24 c.107C > T het (m) 3 p.Thr36Met 3 yrs + 5 mths
c.6992 T >A het (p) 43 p.Ile2331Lys
F25 P25 c.2167C > T het 22 p.Arg723Cys 6 yrs + neonate
c.8870 T > C het 58 p.Ile2957Thr
F26 P26 c.9370C > T het (m) 59 p.His3124Tyr KTx:11 yrs + 3 mths
c.(5236 + 1_5237–1)_(5751 + 1_5752–1)dup, het 33–35 abnormal transcript
F27 P27 c.1-43098_8643-31del het (p) 1–55 no transcript † 10 wsc + IU
c.10174C > T het (m) 61 p.Gln3392*
F28 P28 c.8114delG het (m) 5 p.Gly2705Valfs*11 26 yrs – 4 yrs
Fam. Kidney length at dg
[SDS, right-left] (age)
Diameter of the largest
renal cyst (age)
Last kidney lengtha
[SDS, right-left] (age)
Renal function
(age)
HT (age) Liver involvement
(age)
F1 +6.55;+8.67 (6 mths) 10 mm (6 mths) ND ESRD (2 yrs) + (6 mths) HM, ELE (0.5 yr)
F2 +8.45;+8.45 (1 d) 6 mm (1 d) ND CRF II. (8 yrs) + (1 mth) CHS, HM, ELE, F (2 yrs)
F3 +8.71;+8.71 (5 ds) 18 mm (5 ds) NA RF (6 ds) – CHS, LC, HM (4ds)
F4 +2.4;+3.07 (2 mths) <10 mm (2 mths) +4.08;+5.83 (6 yrs) N (8 yrs) + (1 d) HM, AS (2 mths)
F5 +3.1;+3.1 (4 yrs) 2 mm (4 yrs) +2.59;+1.05 (9 yrs) N (11 yrs) – LC (4 yrs)
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Screening for second locus CNVs
Patients without biallelic PKHD1 mutations were re-
evaluated based on their most recent phenotype, and
were screened for second locus mutations accordingly.
Deletions of NPHP1 and HNF1B were tested by
QMPSF analysis as described previously [12, 35].
Similarly, continuous gene deletion of TSC2 and PKD1
was screened by QMPSF analysis, with the primers
listed in Suppl. Table 1, according to the protocol of
NPHP1-QMPSF [35] with the differences detailed in
Suppl. Methods. The deletion of PKD1 was validated
with MLPA, using the SALSA MLPA probemix P352
PKD1-PKD2, performed according to the manufacturer’s
i n s t r u c t i on s (MRC-Ho l l and , Ams t e r d am , t h e
Netherlands).
Screening for second locus (PKD1, PKD2, HNF1B
and TMEM67) small-scale mutations
Coding exons and intronic junctions of HNF1B and
TMEM67 were Sanger sequenced. A dominant polycystic
kidney panel was designed using the Ion AmpliSeq
Designer version 4.2.1 (Thermo Fischer Scientific,
Waltham, MA). Sample enrichment was performed by the
Ion AmpliSeq Library Kit (Thermo Fischer Scientific).
Samples were barcoded and sequenced on IonTorrent 316
chip (Thermo Fischer Scientific). More than 95% of the
target sequence was covered at least 50-fold. Putative
disease-causing genetic variants were validated by Sanger
sequencing.
Clinical exome sequencing
Clinical exome sequencing was performed as described pre-
viously [36]. More than 95% of the target sequence was cov-
ered at least 20-fold. Reads were mapped against the human
NCBI37/hg19 reference genome. DNA alignment and se-
quence variant analysis were carried out using NextGene
Software version 2.4.2 (SoftGenetics, State College, PA).
Data from the proband was filtered for coding and splicing
region mutations of known/putative genes associated with
cystic kidney diseases.
Results
PKHD1 mutations
Of the 36 unrelated patients with a clinical diagnosis of
ARPKD, 27 (75%) were found to carry biallelic PKHD1 mu-
tations (Table 1). Among them, 25 patients carried biallelic
point mutations (P1–25) and two were compound heterozy-
gous for a point mutation and either a duplication of exons 33–
35 (P26) or a large deletion encompassing exons 1 to 55
(P27). Furthermore, one patient (P28) was found to carry a
single heterozygous frameshift mutation. No PKHD1 muta-
tion was found in 8 families (Table 2, Fig. 1).
Two mutations, p.Thr36Met and p.Ser2639* were found
frequently, in 15/54 (28%) and in 8/54 (15%) of the mutated
alleles, respectively. Seven mutations were novel: besides the
duplication of exons 33–35 and the deletion of exons 1–55,
three truncating mutations (c.5_8delCTGC, p.Ala3Glyfs*2;
Table 1 (continued)
F6 +12.82;+12.82 (4 ds) 3 mm (4 ds) +8.96;+8.96 (3 mths) ESRD (3 mths) + (1 d) mild HM (4 ds)
F7 +2.42;+2.42 (4 ds) ND ND RF (4 ws) – HM (4 ds)
F8 +14.42;+14.42 (4 ds) 5 mm (1 mth) ND RF (6 ws) + (1 d) –
F9 +6.47;+5.09 (1 d) 4 mm (1 d) NA NA – mild HM, ELE, AS (1 d)
F10 +12.36;+12.36 (1 d) 4 mm (3 ds) +7.88;+7.88 (3 yrs) ESRD (4 yrs) + (1 w) LTx:4 yrs
F11 +9;+9 (1 mth) 6 mm (1 mth) +8.77;+6.59 (12 yrs) CRF IV. (12 yrs) + (3 mths) ELE (1 mth)
F12 +4.85;+4.85 (10 yrs) 5 mm (10 yrs) +4.46;+4.46 (18.5 yrs) ESRD (25 yrs) + (10 yrs) LTx:25 yrs
F13 +0.05;+1.8 (3 mths) 6 mm (8 yrs) +5.15;+7.5 (14 yrs) N (14 yrs) – –
F14 +2.59;+3.8 (5 mths) 1 mm (9 yrs) +8.28;+10.08 (15 yrs) CRF II. (15 yrs) + (3 yrs) –
F15 +9.69;+9.69 (5 mths) 9 mm (5 mths) +19.16;+19.16 (6 yrs) CRF III. (6 yrs) + (1 d) LC (1 d), AS, HM (3 yrs)
F16 +5.24;+5.24 (3 yrs) 4 mm (3 yrs) +3.83;3.83 (8 yrs) N (8 yrs) – –
F17 +3.8;+3.8 (4 mths) 10 mm (4 mths) +6.21;+6.21 (5 yrs) N (5 yrs) – –
F18 +1.59;+3.64 (16 yrs) 11 mm (16 yrs) ND CRF II. (17 yrs) – AS (16 yrs)
F19 +12.36;+12.36 (1 d) 8 mm (1 d) +16.79;+16.79 (1 w) RF (1 w) + (1 d) –
F20 +4.01;+4.01 (4 mths) 3 mm (4 mths) +10.31;9.1(4.5 yrs) CRF II. (4.5 yrs) + (1d) AS (4 mths), F (10 mths),
HSM (1 yr)
F21 +18.87;+18.87 (1 d) 4 mm (1 d) NA NA ND –
F22 +4.79;+4.79 (8 ds) 1 mm (8 ds) +21.95;+21.95 (1 yr) ESRD (1 yr) + (1 d) F (1 d), ELE (3 mths)
F23 +15.09;+15.09 (2 ds) 4 mm (2 ds) ND RF (6 ws) + (1 d) –
F24 +0.2;+0.2 (6 mths) 4 mm (6 mths) −1.75;-1.75 (3 yrs) CRF II (1.5 yrs) – –
F25 +5.92;+5.92 (5 mths) 8 mm (5 mths) +10.6;+10.6 (6 yrs) ESRD (6 yrs) + (1 yr) HSM (5 mths), LC (3 yrs)
F26 +9.24;+4.48 (3mths) 10 mm (3 mths) ND ESRD (11 yrs) + (3 mths) LC, HM (3 mths)
F27 +4,1;+4,1 (1 d) ND ND RF (10 ws) + (1 d) –
F28 +7.26;+3.26 (4 yrs) 10 mm (4 yrs) +3.73;+3.73 (26 yrs) CRF II. (26 yrs) + (17 yrs) F, HM, ELE (4 yrs)
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c . 5 0 8 8 d e l TG , p .G l y 1 6 9 6 f s * 1 ; c . 1 2 0 3 6 d e lA ,
p.Gly4013Alafs*24) and two missense mutations
(c .4328G > A, p .Cys1443Tyr and c .10621A > T,
p.Asn3541Tyr). We considered these two latter to also be
pathogenic, because neither is reported in the gnomAD data-
base, both affect amino acids conserved in mammals and are
predicted to be pathogenic by Polyphen-2 (score: 1.0 and
0.981, respectively) and MutationTaster.
Second locus mutations
All eight families without PKHD1 mutations were found to
carry second locus mutations (Table 2, Fig. 1). Three children
diagnosed with hyperechogenic, normal-sized kidneys in
utero or in infancy carried a de novo deletion of HNF1B.
The renal morphology of two children became suggestive of
ADPKD between 2 and 4 years of age. They both harbored de
novo PKD1mutations. One patient (P31) was diagnosed with
tuberous sclerosis at the age of 4 years, and carried a de novo
TSC2/PKD1 deletion. Finally, the phenotype of a patient
(P35) diagnosed at the age of 11 years with end-stage renal
disease was suggestive of juvenile nephronophthisis. He was
compound heterozygous for a complete and a partial deletion
of NPHP1, as described recently [35]. A sibling pair (P36,
P37), diagnosed with hyperechogenic kidneys and hepatic
fibrosis, was homozygous for the frequent TMEM67missense
mutation, p.Cys615Arg [21] (for the calculations, genotype
information from only one of them was used). They had no
neurological involvement. The patient with a heterozygous
PKHD1mutation (P28) was not found to carry a second locus
mutation, even by clinical exome sequencing, which also well
covered the coding regions of NPHP2, NPHP3, andWDR19/
NPHP13. The mutational screening procedure is summarized
in Fig. 1.
Phenotype of patients with PKHD1 and second locus
mutations
Of the 27 patients with PKHD1mutations, 19 children (70%)
developed perinatal respiratory failure, and nine (33%) died
perinatally (< 3 months of age) (Table 1). In contrast, only one
of the nine patients (from eight families) with second locus
mutations had a transient perinatal respiratory failure, second-
ary to an infection (Table 2). Among the perinatal cases who
survived beyond that period, all but one of the ten children
with PKHD1mutations developed hypertension by the age of
1 year, compared with none of the six patients with second
locus mutations (Table 1). A mean kidney length above + 4
SD at diagnosis was also specific for PKHD1-associated
ARPKD: 19 of 27 patients (70%) with biallelic PKHD1 mu-
tations, but none of the nine patients with second locus muta-
tions had such an enlarged kidney. Based on these data, the
phenotype of the patient with a single heterozygous PKHD1
mutation (P28) is highly suggestive of a moderate PKHD1-
associated ARPKD: she developed hypertension at an early
stage, as well as highly enlarged kidneys and hepatic fibrosis.
There was no difference in the renal survival between patients
with PKHD1mutations who survived the perinatal period and
the heterogeneous group of patients with second locus muta-
tions (Tables 1 and 2, Fig. 2).
Discussion
Here we aimed to investigate the reason for the high propor-
tion of ARPKD cases negative for PKHD1 point mutations.
Our PKHD1-positive rate of 78%—including a patient with a
single heterozygous mutation—corresponds well to previous
reports [15, 16, 27, 29, 32, 33]. We first assessed the potential
role of PKHD1 CNVs, but found no biallelic CNVs in the
PKHD1 negative cases. This finding was in accordance with
Fig. 1 Mutational screening procedure in children with the clinical
diagnosis of autosomal recessive polycystic kidney disease (ARPKD)
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the low prevalence of PKHD1 CNVs in other cohorts [15, 16,
26, 27, 30, 31]. We only found a three-exon duplication and a
large deletion in two out of three patients with a single hetero-
zygous PKHD1 point mutation. Duplications are extremely
rare; here, we present only the second such case [26]. These
results emphasize that screening for CNVs is primarily impor-
tant in patients with a heterozygous PKHD1 point mutation.
To identify all mutations of the coding regions, we used the
most sensitive but also labor- and time-consuming methods of
Sanger sequencing and MLPA analysis. However, excluding
the causal role of PKHD1 intronic and promoter mutations or
rearrangements in patients with or without a single heterozy-
gous mutation is especially challenging by direct genetic tests.
Therefore, we aimed to identify the causal mutations in all
patients with a clinical diagnosis of ARPKD, and thus exclude
the causal role of PKHD1 indirectly. We found all patients
without PKHD1mutations to carry causal mutations in second
loci, by re-evaluation of the phenotype and targeted mutation
screening, indicating that 22% of the initial clinical ARPKD
diagnoses were false. We failed to identify in the third child
with a heterozygous PKHD1 mutation a second locus muta-
tion, even following clinical exome sequencing that also cov-
ered the promoter region of PMM2 [4]. This is in accordance
with the phenotype which is strongly suggestive of PKHD1-
associated ARPKD. Her case thus points on the difficulty in
identifying some PKHD1 mutations even by the combined
approach of sequencing and MLPA, and suggests a potential
role of an intronic or a regulatory PKHD1 mutation.
The successful identification of second locus mutations in
negative cases by direct genetic tests emphasizes the impor-
tance of their thorough re-phenotyping. The differential diag-
nosis of mild and moderate forms without extremely enlarged
kidneys and respiratory failure can be challenging at diagno-
sis. Within this cohort, an infant-onset hypertension was high-
ly suggestive of PKHD1-associated ARPKD.
In accordance with the literature, the phenotype of patients
with PKHD1 mutations strongly correlated with the causal
mutations; no patient survived the perinatal period with
biallelic loss-of-function mutations [16, 37, 38].
Interestingly, a patient, compound heterozygous for a second
and a last exon truncating mutation, p.Gly4013Alafs*24
(P14), presented with a moderate phenotype: she was diag-
nosed at the age of 5 months and had a normal GFR at the age
of 9 years, indicating that the loss of the C-terminal 62 amino
acids of fibrocystin does not cause complete loss of function.
The intracellular C-terminal part of fibrocystin consists of 192
amino acids and is known to modulate the mTOR pathway
[39]. It also contains the ciliary targeting sequence
(p.3876_3893CLVCCWLKRSKSRKTKPE), that remains
unaffected in the Gly4013Alafs*24 fibrocystin [40]. Along
the same lines as the hypomorphic nature of this C-terminal
truncation, mice lacking the last exon (exon 67), which en-
codes the nuclear localization signal and the polycystin 2
binding domain, develop a normal phenotype [41].
In conclusion, we found one quarter of the ARPKD
cases to be phenocopies, caused by second locus muta-
tions. Our data suggest that perinatal respiratory failure,
a kidney length > + 4 SD and early-onset hypertension
increase the likelihood of PKHD1-associated ARPKD.
The phenotype of cases that are negative on PKHD1
sequencing should first be re-evaluated. We recommend
screening for PKHD1 CNVs in patients with a heterozy-
gous point mutation and in families with an unequivocal
phenotype.
Fig. 2 Renal survival of patients
with PKHD1 and second locus
mutations. No difference was
found in the renal progression
between patients with PKHD1
and second locus mutations (p =
0.51). Among patients with
second locus mutations, those
with PKD1 and HNF1B
mutations were young (≤
11 years), and patients with
nephronophthisis reached end-
stage renal disease between 9 and
19 years of age, giving a worse
renal survival curve than
generally expectable
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